S-23 Mastorin Research Overview
What Is S-23 Mastorin?
S-23 Mastorin is a non-steroidal selective androgen receptor modulator investigated in controlled laboratory and preclinical models involving high-affinity androgen-receptor binding, transcriptional activation, tissue selectivity, pharmacokinetics and reproductive signalling.
The compound is generally identified as S-23 or S23. Mastorin is the commercial product name used by BioPlex Peptides for its S-23 research capsules.
S-23 belongs to the arylpropionamide family of non-steroidal androgen-receptor ligands. Its chemical structure is related to the wider development of compounds designed to produce different androgen-receptor responses across separate tissues.
The principal molecular characteristics of S-23 include:
Compound name—S-23, Commercial name—Mastorin, Chemical class—Non-steroidal arylpropionamide, Research classification—Selective androgen receptor modulator, Molecular formula—C₁₈H₁₃ClF₄N₂O₃, Approximate molecular weight—416.76 g/mol, CAS number—1010396-29-8, Principal research target—Androgen receptor.
S-23 is considered a genuine SARM because its principal molecular target is the androgen receptor. This separates it mechanistically from MK-677 Ibutamoren, Cardarine GW-501516, SR-9009 and SR-9011.
Those compounds may be displayed within wider SARMs collections because of established market categorisation, but they do not all work through selective androgen-receptor modulation.
Researchers searching for S-23 UK, S-23 for sale UK, Mastorin for sale or where to buy S-23 should understand that its public evidence base is principally preclinical. It should not be presented as an approved compound or reduced to unsupported claims about guaranteed outcomes.
This S-23 Mastorin research overview examines its molecular identity, receptor-binding profile, tissue-selectivity research, pharmacokinetics, reproductive-signalling studies, analytical requirements and current evidence limitations.
How S-23 Works in Research
The androgen receptor is a ligand-activated nuclear receptor involved in the regulation of androgen-responsive gene transcription.
When a compatible ligand binds to the receptor, the receptor can undergo a conformational change, reorganise its associated regulatory proteins and move towards the nucleus.
The activated receptor complex may then interact with androgen-response elements associated with DNA. Transcriptional co-activators and co-repressors influence which androgen-responsive genes are affected and the degree of the resulting response.
Principal stages of androgen-receptor signalling include:
Ligand binding, Receptor conformational change, Reorganisation of chaperone proteins, Nuclear translocation, Interaction with androgen-response elements, Recruitment of transcriptional regulators, Altered androgen-responsive gene expression.
S-23 has been characterised as a high-affinity androgen-receptor ligand. Published preclinical research reported binding within the low-nanomolar range, indicating strong interaction with the receptor under the assay conditions used.
Binding affinity does not independently establish the complete biological response produced by a compound.
Researchers must also examine:
Receptor activation, Transcriptional efficacy, Concentration-response behaviour, Tissue distribution, Metabolism, Exposure duration, Co-regulator recruitment, Functional tissue measurements.
S-23 can activate androgen-receptor-mediated transcription in suitable cellular reporter systems. However, the degree of activation may vary according to receptor density, cell type, experimental concentration and the reporter construct selected.
A receptor-binding experiment measures molecular interaction. A transcriptional assay measures a downstream functional response. These measurements are connected but should not be treated as identical.
What Does High Androgen-Receptor Affinity Mean?
Binding affinity describes how strongly a ligand interacts with a receptor under defined experimental conditions.
The inhibition constant, commonly abbreviated as Ki, is one measurement used to describe this interaction. A lower Ki value generally indicates stronger measured affinity within that assay system.
S-23 has been reported to bind the androgen receptor with a Ki value of approximately 1.7nM in published research.
This value should be interpreted carefully.
A strong binding measurement does not automatically mean that S-23 produces the greatest response in every tissue or experimental model. Biological activity also depends on compound concentration, receptor availability, transcriptional efficacy, metabolism and tissue exposure.
Researchers comparing S-23 with S-4 Andarine, Ostarine MK-2866, LGD-4033 Ligandrol or RAD-140 Testolone should therefore avoid ranking compounds solely by one receptor-affinity value.
A complete comparison should examine:
Receptor-binding affinity, Functional receptor activation, Tissue-selectivity measurements, Pharmacokinetic behaviour, Concentration-response curves, Experimental duration, Model selection, Published evidence quality.
High receptor affinity provides useful molecular information, but it does not independently establish tissue selectivity, functional outcomes or overall evidence quality.
Tissue Selectivity in S-23 Research
Tissue selectivity refers to relative differences in androgen-receptor-associated activity across separate tissues.
It does not mean that a SARM acts exclusively within skeletal-muscle or bone models. It also does not guarantee the complete absence of activity within reproductive or other androgen-responsive tissues.
S-23 research has examined activity across skeletal-muscle, reproductive and endocrine-associated measurements.
Its preclinical profile is particularly useful for demonstrating why the word selective must be interpreted carefully. S-23 can produce androgen-receptor-associated activity across several tissues, but the magnitude and character of the response may differ according to the experimental model and concentration.
Factors influencing tissue selectivity include:
Local androgen-receptor concentration, Transcriptional co-activator availability, Transcriptional co-repressor availability, Ligand metabolism, Tissue distribution, Receptor conformation, Exposure duration, Baseline endocrine conditions, Gene accessibility.
Two tissues containing androgen receptors may produce different responses after exposure to the same ligand.
The variation can result from differences in receptor expression, intracellular enzymes, regulatory proteins and the genes available for transcription.
Researchers should therefore describe S-23 as a tissue-selective androgen receptor modulator without implying that its activity is confined to one type of tissue.
What Researchers Study S-23 For
S-23 has been investigated across several connected areas of androgen-receptor research.
Principal S-23 research areas include:
Androgen-receptor binding, Transcriptional activation, Tissue-selectivity analysis, Skeletal-muscle measurements, Reproductive signalling, Endocrine-marker responses, Pharmacokinetics, Oral bioavailability, Compound metabolism, Recovery-associated measurements.
Much of the frequently cited evidence originates from a specialised preclinical study examining S-23 as a possible research compound for hormonal contraceptive development.
This research evaluated receptor binding, pharmacokinetics, androgen-responsive tissues, reproductive measurements and recovery after the experimental exposure period.
The findings are scientifically valuable because they provide information about S-23 across a complete biological research model rather than relying only on an isolated receptor-binding assay.
However, the results remain model-specific and preclinical. They should not be converted into personal-use instructions, general claims or guaranteed outcomes.
S-23 and Skeletal-Muscle Research
S-23 has been examined in androgen-responsive skeletal-muscle models, including measurements involving the levator ani muscle.
The levator ani assay has historically been used to compare anabolic and androgenic responses in preclinical androgen research. It can provide information about the activity of a compound within a defined androgen-responsive muscle.
Researchers may measure:
Muscle weight, Tissue growth, Protein-expression markers, Androgen-receptor activity, Gene transcription, Fibre dimensions, Functional-force variables, Lean-tissue measurements.
A change in the weight of one androgen-responsive muscle does not independently establish the same response across every skeletal-muscle group.
Researchers should consider the model, baseline endocrine state, exposure period and reference compound used for comparison.
Molecular, structural and functional endpoints should ideally be evaluated together. An increase in tissue weight does not automatically demonstrate a proportional increase in functional performance.
S-23 and Reproductive-Signalling Research
A distinctive part of the S-23 evidence base concerns reproductive and endocrine signalling.
Preclinical research examined whether S-23, when investigated within a defined hormonal model, influenced sperm-associated measurements and reproductive-tissue variables.
These experiments were designed around a specialised research objective and should not be interpreted as general information about uncontrolled exposure.
Measurements examined in reproductive-signalling research may include:
Sperm concentration, Testicular measurements, Gonadotropin-associated markers, Reproductive-tissue weight, Androgen-dependent behaviour, Recovery after exposure, Endocrine feedback variables.
The available findings suggest that S-23 can affect reproductive signalling under the conditions studied. This provides important evidence that tissue-selective androgen-receptor modulation does not mean activity limited to muscle or bone.
Research involving suppression and subsequent recovery requires particularly careful interpretation.
The time required for a measurement to change, stabilise or recover can depend on the selected concentration, duration, experimental model and background hormonal conditions.
Findings from one preclinical study cannot establish universal reversibility across different research environments.
S-23 Pharmacokinetic Research
Pharmacokinetics describes how a compound is absorbed, distributed, metabolised and eliminated within an experimental system.
S-23 has been investigated for oral bioavailability and pharmacokinetic behaviour in preclinical models.
Relevant pharmacokinetic measurements include:
Maximum measured concentration, Time to maximum concentration, Exposure over time, Apparent half-life, Oral bioavailability, Tissue distribution, Metabolite formation, Elimination pattern.
Pharmacokinetic measurements help researchers design suitable sampling schedules and determine whether biological endpoints correspond with measurable compound exposure.
A compound with strong receptor affinity may still produce different experimental responses if its absorption, metabolism or tissue distribution changes.
The pharmacokinetic profile of properly characterised research material should not automatically be attributed to every commercial S-23 product. Differences in identity, purity, formulation and capsule-content uniformity can affect experimental reproducibility.
S-23 Compared With S-4 Andarine
S-23 and S-4 Andarine are both genuine non-steroidal selective androgen receptor modulators, but they should not be treated as the same compound.
S-4 is also known as Andarine or GTx-007. It was investigated during the earlier development of arylpropionamide SARMs and has a molecular formula of C₁₉H₁₈F₃N₃O₆.
S-23 has a molecular formula of C₁₈H₁₃ClF₄N₂O₃ and a different molecular structure, receptor-affinity profile and preclinical research history.
Principal distinctions include:
S-4 is commonly called Andarine, S-23 is commercially called Mastorin by BioPlex, S-23 has been reported as a high-affinity androgen-receptor ligand, S-23 has specialised reproductive-signalling research, The compounds have different formulas and molecular weights, Their evidence should be assessed independently.
S-23 should not be marketed simply as a stronger version of S-4. Stronger is not a complete scientific classification and can refer to receptor affinity, transcriptional activity, tissue response or a selected experimental endpoint.
A scientifically useful comparison must specify which measurement is being discussed.
S-23 Compared With Ostarine and LGD-4033
Ostarine MK-2866 and LGD-4033 Ligandrol have more developed public research profiles than S-23.
Ostarine has appeared in several controlled investigations involving lean-tissue and functional measurements. LGD-4033 has published controlled research involving pharmacokinetics and concentration-dependent biological endpoints.
S-23 is supported principally by laboratory and preclinical evidence.
This does not make its research profile unimportant. It means that claims about S-23 should be qualified according to the available level of evidence.
Evidence should be separated into:
Molecular-binding evidence, Cellular transcriptional evidence, Preclinical evidence, Controlled clinical evidence, Independent replication, Analytical product evidence.
A compound with strong preclinical receptor activity should not automatically be presented as having the same evidence base as a compound investigated in controlled clinical research.
How Researchers Identify S-23
Correct analytical identification is important because S-23 may be confused with S-4, S-22 or other similarly named research compounds.
S-23 can be analysed using complementary laboratory techniques.
HPLC may help assess chromatographic purity. Liquid chromatography–mass spectrometry can support molecular-identity analysis. Nuclear magnetic resonance spectroscopy may provide more detailed structural confirmation.
Relevant analytical information includes:
Correct compound name, Molecular formula, Expected molecular mass, CAS number, Chromatographic purity, Mass-spectrometry identity, Batch number, Capsule strength, Capsule-content uniformity, Storage conditions.
Purity and identity are separate analytical questions.
A sample can produce one dominant chromatographic peak without that peak necessarily representing S-23. Identity testing should therefore accompany purity analysis wherever possible.
For capsule-based research materials, content-uniformity analysis can help establish whether the declared amount is distributed consistently across the batch.
What Should Researchers Check When Buying S-23 in the UK?
Researchers searching for S-23 for sale UK, Mastorin for sale, buy S-23 UK or where to buy S-23 should examine the technical identity and documentation of the product.
Researchers should check:
Correct S-23 naming, CAS number 1010396-29-8, Molecular formula C₁₈H₁₃ClF₄N₂O₃, Approximate molecular weight 416.76 g/mol, Declared capsule strength, Number of capsules, Batch information, Purity documentation, Identity testing, UK manufacturing or encapsulation information, Storage guidance, Supplier traceability.
The BioPlex S-23 Mastorin research product provides 50 capsules with a declared strength of 15mg per capsule for controlled laboratory and analytical research.
Researchers comparing SARMs for sale UK should not select material solely according to price, capsule quantity or marketing descriptions.
A responsible comparison should consider whether the supplier provides registered business information, accessible contact details, clear research-only classification, batch traceability and technically consistent product information.
Search phrases such as S-23 UK and buy S-23 UK may help locate available suppliers, but they do not verify product identity or experimental suitability.
Limitations of Current S-23 Research
S-23 has a focused but relatively limited evidence base.
The principal research provides useful information involving androgen-receptor affinity, transcriptional activation, pharmacokinetics and reproductive signalling. However, several limitations remain.
Important limitations include:
Reliance on preclinical models, Limited controlled clinical research, Small number of principal published studies, Model-specific endocrine conditions, Uncertainty surrounding extended exposure, Limited independent replication, Differences between research material and commercial products, Reliance on surrogate endpoints.
Researchers should also distinguish between a compound’s molecular research profile and the quality of a product sold under the same name.
Published findings involving correctly identified S-23 do not verify every capsule or powder advertised online. Batch-specific identity, purity and content analysis remain necessary.
Future S-23 research would benefit from independent replication, standardised analytical characterisation, broader concentration-response analysis and clearly reported pharmacokinetic data.
Conclusion
S-23 Mastorin is a non-steroidal selective androgen receptor modulator investigated for high-affinity androgen-receptor binding, transcriptional activity, tissue-selective signalling, pharmacokinetics and reproductive-associated endpoints.
Its molecular formula is C₁₈H₁₃ClF₄N₂O₃, its approximate molecular weight is 416.76 g/mol and its CAS number is 1010396-29-8.
S-23 is a genuine SARM because it interacts with the androgen receptor. However, its evidence profile is principally preclinical and should be distinguished from the more developed published research surrounding Ostarine or LGD-4033.
High androgen-receptor affinity does not establish universal strength or predict every tissue response. Researchers must also consider transcriptional activity, exposure, metabolism, tissue distribution and the selected experimental model.
S-23 should not be treated as interchangeable with S-4 Andarine, Ostarine S-22 or other compounds sharing similar naming conventions.
Researchers considering S-23 for sale UK should examine molecular identity, capsule strength, batch documentation, chromatographic purity, mass-spectrometry evidence and supplier transparency before selecting a laboratory material.
Continue Exploring...
Explore S-23 Mastorin Research Capsules ⟶
Explore S-4 Andarine Research Capsules ⟶
Explore the BioPlex SARMs Research Collection ⟶
Read the Complete SARMs UK Research Compound Guide ⟶
Learn More About BioPlex Peptides ⟶
All discussion is presented strictly for educational and scientific research purposes only, supporting informed study, data interpretation, and responsible laboratory investigation.
